Cargando…

Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule

BACKGROUND & PURPOSE: Although rare, cutaneous lymphomas represent a separate entity in hematologic oncology. T cell origin lymphomas are most common, with Mycosis Fungoides (MF) accounting for about 50–70% of cases. Sezary Syndrome (SS), which represents the leukemic varian of MF, accounts for...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgakopoulos, Ioannis, Papadavid, Evaggelia, Platoni, Kalliopi, Dilvoi, Maria, Patatoukas, George, Kypraiou, Efrosyni, Nikolaou, Vasiliki, Efstathopoulos, Efstathios, Kelekis, Nikolaos, Kouloulias, Vasilios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293019/
https://www.ncbi.nlm.nih.gov/pubmed/30582018
http://dx.doi.org/10.1016/j.ctro.2018.12.002
_version_ 1783380479561433088
author Georgakopoulos, Ioannis
Papadavid, Evaggelia
Platoni, Kalliopi
Dilvoi, Maria
Patatoukas, George
Kypraiou, Efrosyni
Nikolaou, Vasiliki
Efstathopoulos, Efstathios
Kelekis, Nikolaos
Kouloulias, Vasilios
author_facet Georgakopoulos, Ioannis
Papadavid, Evaggelia
Platoni, Kalliopi
Dilvoi, Maria
Patatoukas, George
Kypraiou, Efrosyni
Nikolaou, Vasiliki
Efstathopoulos, Efstathios
Kelekis, Nikolaos
Kouloulias, Vasilios
author_sort Georgakopoulos, Ioannis
collection PubMed
description BACKGROUND & PURPOSE: Although rare, cutaneous lymphomas represent a separate entity in hematologic oncology. T cell origin lymphomas are most common, with Mycosis Fungoides (MF) accounting for about 50–70% of cases. Sezary Syndrome (SS), which represents the leukemic varian of MF, accounts for 3% of Cutaneous T Cell Lymphomas (CTCL). Total Skin Electron Beam Therapy (TSEB) is included at the mainstream of treatment choices for CTCL. The scope of this study is to evaluate the effectiveness and toxicity of two treatment schedules of TSEB. METHODS AND MATERIALS: We report our experience with TSEB in the management of MF and SS, as of 14 patients treated in our institution from 2011 to 2015. 8 patients received the 12 Gy (low dose) scheme while 6 patients were managed with 36 Gy (standard or full dose scheme) according to six dual field Stanford technique. The endpoints were overall response rate, duration of response and toxicity of treatment. RESULTS: After a median follow up of 2.5 years we noted excellent treatment outcome, with both schemes being well tolerated and resulting in comparable response rates. The overall response rate for both treatment regimens was over 87.5%. Treatment was well tolerated with mild toxicity. CONCLUSION: The role of TSEB in the management of MF and SS is well established. The low dose TSEB schedule of 12 Gy is an effective treatment option, since therapeutic results are more than acceptable, compliance is excellent and toxicity is minimal. Moreover, the evidence that it can be repeated safely makes it more attractive than the standard 36 Gy scheme, when a patient is referred to radiation treatment according to treatment guidelines.
format Online
Article
Text
id pubmed-6293019
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-62930192018-12-21 Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule Georgakopoulos, Ioannis Papadavid, Evaggelia Platoni, Kalliopi Dilvoi, Maria Patatoukas, George Kypraiou, Efrosyni Nikolaou, Vasiliki Efstathopoulos, Efstathios Kelekis, Nikolaos Kouloulias, Vasilios Clin Transl Radiat Oncol Article BACKGROUND & PURPOSE: Although rare, cutaneous lymphomas represent a separate entity in hematologic oncology. T cell origin lymphomas are most common, with Mycosis Fungoides (MF) accounting for about 50–70% of cases. Sezary Syndrome (SS), which represents the leukemic varian of MF, accounts for 3% of Cutaneous T Cell Lymphomas (CTCL). Total Skin Electron Beam Therapy (TSEB) is included at the mainstream of treatment choices for CTCL. The scope of this study is to evaluate the effectiveness and toxicity of two treatment schedules of TSEB. METHODS AND MATERIALS: We report our experience with TSEB in the management of MF and SS, as of 14 patients treated in our institution from 2011 to 2015. 8 patients received the 12 Gy (low dose) scheme while 6 patients were managed with 36 Gy (standard or full dose scheme) according to six dual field Stanford technique. The endpoints were overall response rate, duration of response and toxicity of treatment. RESULTS: After a median follow up of 2.5 years we noted excellent treatment outcome, with both schemes being well tolerated and resulting in comparable response rates. The overall response rate for both treatment regimens was over 87.5%. Treatment was well tolerated with mild toxicity. CONCLUSION: The role of TSEB in the management of MF and SS is well established. The low dose TSEB schedule of 12 Gy is an effective treatment option, since therapeutic results are more than acceptable, compliance is excellent and toxicity is minimal. Moreover, the evidence that it can be repeated safely makes it more attractive than the standard 36 Gy scheme, when a patient is referred to radiation treatment according to treatment guidelines. Elsevier 2018-12-06 /pmc/articles/PMC6293019/ /pubmed/30582018 http://dx.doi.org/10.1016/j.ctro.2018.12.002 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Georgakopoulos, Ioannis
Papadavid, Evaggelia
Platoni, Kalliopi
Dilvoi, Maria
Patatoukas, George
Kypraiou, Efrosyni
Nikolaou, Vasiliki
Efstathopoulos, Efstathios
Kelekis, Nikolaos
Kouloulias, Vasilios
Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule
title Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule
title_full Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule
title_fullStr Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule
title_full_unstemmed Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule
title_short Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule
title_sort clinical application of total skin electron beam (tseb) therapy for the management of t cell cutaneous lymphomas. the evolving role of low dose (12 gy) treatment schedule
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293019/
https://www.ncbi.nlm.nih.gov/pubmed/30582018
http://dx.doi.org/10.1016/j.ctro.2018.12.002
work_keys_str_mv AT georgakopoulosioannis clinicalapplicationoftotalskinelectronbeamtsebtherapyforthemanagementoftcellcutaneouslymphomastheevolvingroleoflowdose12gytreatmentschedule
AT papadavidevaggelia clinicalapplicationoftotalskinelectronbeamtsebtherapyforthemanagementoftcellcutaneouslymphomastheevolvingroleoflowdose12gytreatmentschedule
AT platonikalliopi clinicalapplicationoftotalskinelectronbeamtsebtherapyforthemanagementoftcellcutaneouslymphomastheevolvingroleoflowdose12gytreatmentschedule
AT dilvoimaria clinicalapplicationoftotalskinelectronbeamtsebtherapyforthemanagementoftcellcutaneouslymphomastheevolvingroleoflowdose12gytreatmentschedule
AT patatoukasgeorge clinicalapplicationoftotalskinelectronbeamtsebtherapyforthemanagementoftcellcutaneouslymphomastheevolvingroleoflowdose12gytreatmentschedule
AT kypraiouefrosyni clinicalapplicationoftotalskinelectronbeamtsebtherapyforthemanagementoftcellcutaneouslymphomastheevolvingroleoflowdose12gytreatmentschedule
AT nikolaouvasiliki clinicalapplicationoftotalskinelectronbeamtsebtherapyforthemanagementoftcellcutaneouslymphomastheevolvingroleoflowdose12gytreatmentschedule
AT efstathopoulosefstathios clinicalapplicationoftotalskinelectronbeamtsebtherapyforthemanagementoftcellcutaneouslymphomastheevolvingroleoflowdose12gytreatmentschedule
AT kelekisnikolaos clinicalapplicationoftotalskinelectronbeamtsebtherapyforthemanagementoftcellcutaneouslymphomastheevolvingroleoflowdose12gytreatmentschedule
AT koulouliasvasilios clinicalapplicationoftotalskinelectronbeamtsebtherapyforthemanagementoftcellcutaneouslymphomastheevolvingroleoflowdose12gytreatmentschedule